Highlights• A protein called polycystin-1 may help shepherd another protein, polycystin-2, to a cell’s antenna, or cilium. This process is defective in induced pluripotent stem cells derived from patients with autosomal dominant polycystic kidney disease.• Placement of the normal polycystin-1 protein back into cells can correct this defect.• Pluripotent stem cells from polycystic kidney patients may be useful as “disease in a dish” models for developing new therapeutics.
Autosomal dominant polycystic kidney disease affects one in every 600 adults and is characterized by numerous cysts on the kidneys.
Newswise — Washington, DC (September 5, 2013) — New research has uncovered a process that is defective in patients with autosomal dominant polycystic kidney disease, a common cause of kidney failure. The findings, which appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN), point to a new potential strategy for preventing and treating the disease.
Polycystic kidney disease (PKD), the fourth leading cause of kidney failure worldwide, comes in two forms: autosomal dominant polycystic kidney disease (ADPKD) develops in adulthood and is quite common, while autosomal recessive polycystic kidney disease (ARPKD) is rare but frequently fatal. ADPKD is caused by mutations in either of two proteins, polycystin-1 and polycystin-2, while ARPKD is caused by mutations in a protein called fibrocystin. There is no cure or widely adopted clinical therapy for either form of the disease.
Polycystin-1, polycystin-2, and fibrocystin are all found in a cell’s primary cilium, which acts as the cell’s antenna and is intimately involved in human embryonic development as well as the development of certain diseases, including PKD. “What we don’t know, and were hoping to better understand, is what goes wrong with these proteins in the cells of PKD patients and what kinds of therapies might help those cells,” said Joseph Bonventre, MD, PhD (Brigham and Women’s Hospital).
Dr. Bonventre and his colleagues Benjamin Freedman, PhD and Albert Lam, MD led a team of scientists at Brigham and Women’s Hospital, the Mayo Clinic, and the Harvard Stem Cell Institute as they studied cells obtained from five PKD patients: three with ADPKD and two with ARPKD. The investigators reprogrammed patients’ skin cells into induced pluripotent stem cells, which can give rise to many different cell types and tissues. When the researchers examined these cells under the microscope, they discovered that the polycystin-2 protein traveled normally to the antenna, or cilium, in cells from ARPKD patients, but it had trouble reaching the antenna in ADPKD patients. When they sequenced the DNA in these ADPKD patient cells, the investigators found mutations in the gene that encodes polycystin-1, suggesting that polycystin-1 helps shepherd polycystin-2 to the cilium.
“When we added back a healthy form of polycystin-1 to our patient cells, it traveled to the cilium and brought its partner polycystin-2 with it, suggesting a possible therapeutic approach for PKD,” explained Dr. Freedman. “This was the first time induced pluripotent stem cells have been used to study human kidney disease where a defect related to disease mechanisms has been found.”
The researchers noted that reprogrammed stem cells from patients with ADPKD may also be useful for testing new therapeutics before trying them out in humans.
In an accompanying editorial, Alexis Hofherr, MD and Michael Köttgen, MD (University Medical Centre, in Freiburg, Germany) stated that the study has “laid the groundwork for using induced pluripotent stem cells in PKD research. This important step forward will provide novel opportunities to model PKD pathogenesis with human cells with defined patient mutations.”
Study co-authors include Jamie Sundsbak, PhD, Rossella Iatrino, MD, Xuefeng Su, PhD, Sarah Koon, PhD, Maoqing Wu, PhD, Laurence Daheron, PhD, Peter Harris, PhD, and Jing Zhou, MD, PhD.
Disclosures: The authors reported no financial disclosures.
The article, entitled “Reduced Ciliary Polycystin-2 in iPS Cells from PKD Patients with PKD1 Mutations,” will appear online at http://jasn.asnjournals.org/ on September 5, 2013, doi: 10.1681/ASN.2012111089.
The editorial, entitled “Induced Pluripotent Stem Cells from Polycystic Kidney DiseasePatients: A Novel Tool to Model the Pathogenesis of Cystic Kidney Disease,” will appear online at http://jasn.asnjournals.org/ on September 5, 2013, doi: 10.1681/ASN.2013070767
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.Founded in 1966, and with more than 14,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.
# # #